bi_microparts_image

Boehringer’s France restructure will cull over 300 jobs

pharmafile | December 11, 2018 | News story | Manufacturing and Production Boehringer, Sanofi, job cuts, pharma 

Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over 300 employees in France – around 10% of the company’s total workforce in the country.

The German drug company confirmed the plans to unions, explaining that the move is designed to reorganise operations in and around its hub in the French city of Lyon.

The restructure comes in the wake of an asset swap between Boehringer and Sanofi, with the former trading its consumer health division for the latter’s animal health arm Merial last year – a transaction worth $20 billion.

In total, Sanofi intends to axe 327 positions from a total of 2,800, which will also make room for the introduction of 32 new roles. The plan was confirmed by Jean Scheftsik de Szolnok, Boehringer’s Chairman for France, who also noted that those affected would be offered voluntary severance packages, though he could not say exactly when this would be the case.

Matt Fellows

Related Content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …

Sanofi shares phase 2b results for dermatitis treatment

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …

Sanofi to acquire Inhibrx for approximately $1.7bn

Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for …

Latest content